Quality of Life in Patients With Liver Cancer Treated With Image-Guided Therapy

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Steven Meranze, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00482586
First received: June 4, 2007
Last updated: June 3, 2015
Last verified: June 2015
  Purpose

RATIONALE: Gathering information about quality of life over time from patients with liver cancer treated with image-guided therapy may help the study of cancer in the future.

PURPOSE: This clinical trial is gathering information about quality of life over time from patients with liver cancer treated with image-guided therapy.


Condition Intervention
Liver Cancer
Metastatic Cancer
Other: medical chart review
Other: questionnaire administration
Procedure: quality-of-life assessment

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Outcomes Following Image-Guided Therapy for Hepatic Malignancies

Resource links provided by NLM:


Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Development of a data repository for clinical outcome measures by conducting a medical record review at baseline, during routine follow-up after image-guided therapy, and then annually thereafter [ Time Frame: one year ] [ Designated as safety issue: No ]
  • Development of a data repository for health-related quality of life outcome measures by administering the Medical Outcomes Study Short Form questionnaire at baseline, during routine follow-up after image-guided therapy, and then annually thereafter [ Time Frame: one year ] [ Designated as safety issue: No ]

Enrollment: 137
Study Start Date: October 2003
Study Completion Date: April 2015
Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Image-guided Therapy
Patients undergoing Image-guided Therapy of Hepatic Neoplasms.
Other: medical chart review
Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
Other Names:
  • Ablation
  • Embolization
Other: questionnaire administration
Patients with hepatic neoplasms who undergo Image-guided Therapy
Other Names:
  • Ablation
  • Embolization
  • Chemo-embolization
Procedure: quality-of-life assessment
Patients with hepatic neoplasms who undergo Image-guided Therapy
Other Names:
  • Ablation
  • Embolization
  • Chemoembolization

Detailed Description:

OBJECTIVES:

  • Develop a data repository for clinical and health-related quality of life outcome measures in patients with hepatic malignancies treated with image-guided therapies.

OUTLINE: This is a pilot, prospective, longitudinal study.

Patients complete a standard questionnaire assessing health-related quality of life at baseline, during routine follow-up care after image-guided therapy, and then annually thereafter. Health and disease status and the development of other illnesses are assessed by medical record review.

PROJECTED ACCRUAL: Not specified

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with hepatic neoplasms who undergo Image-guided Therapy

Criteria

DISEASE CHARACTERISTICS:

  • Undergoing concurrent image-guided therapy for hepatic malignancies using any of the following imaging techniques:

    • X-ray
    • Ultrasound
    • MRI
    • CT scan
    • Nuclear medicine imaging

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00482586

Locations
United States, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232-6838
Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States, 37064
Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States, 37064
Sponsors and Collaborators
Vanderbilt University
Investigators
Study Chair: Steven G. Meranze, MD Vanderbilt-Ingram Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Steven Meranze, Professor of Radiology, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00482586     History of Changes
Other Study ID Numbers: CDR0000546520, P30CA068485, VU-VICC-GI-0372, VU-VICC-IRB-020874
Study First Received: June 4, 2007
Last Updated: June 3, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Vanderbilt University:
adult primary liver cancer
liver metastases

Additional relevant MeSH terms:
Liver Neoplasms
Neoplasm Metastasis
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms
Neoplasms by Site
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on August 27, 2015